The purpose of this study was to evaluate the impact of CERA treatment by using methoxy polyethylene glycol-epoetin (MPG-EPO) beta on selected CVD risk biomarkers, especially of inflammation and endothelial dysfunction, and left ventricle structure and function, in nondialyzed CKD patients. This evidence concerns the gene EPO and chronic kidney disease.